Analyst Michael Matson of Needham maintained a Buy rating on OrthoPediatrics (KIDS – Research Report), retaining the price target of $42.00.
Michael Matson has given his Buy rating due to a combination of factors discussed during the fireside chat with OrthoPediatrics at the Needham Healthcare Conference. One of the key reasons is the company’s strategic focus on expanding its product offerings, particularly through new implant product launches, which are expected to drive future growth. Additionally, OrthoPediatrics is making significant strides in developing enabling technologies that could enhance its competitive position in the market.
Another factor influencing the Buy rating is the company’s Specialty Bracing segment, which appears to be well-positioned to capitalize on market opportunities. Furthermore, despite concerns about tariff exposure, the company’s proactive measures to mitigate these risks have been viewed positively. Overall, these elements collectively contribute to a favorable outlook for OrthoPediatrics, justifying the Buy recommendation.
In another report released on April 7, Lake Street also initiated coverage with a Buy rating on the stock with a $37.00 price target.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KIDS in relation to earlier this year.